Page 54 - TD-2-3

Tumor Discovery CE-SWI in desmoid fibromatosis assessment

Table 1. Summary of trends in mean, skewness, 10 and 90 percentile proportions in CE‑SWI and T2 and their concordance
th
th
(Y/N) with response category for each of the 10 desmoid fibromatosis patients included in this study
Modality Progression by RECIST T2 Stable RECIST discrepancy with progression Stable RECIST discrepancy with response
Case 1 Case 2 Case 3 Case 4 Case 6 Case 10 Case 5 Case 7 Case 8 Case 9
SWI T2 SWI T2 SWI T2 SWI T2 SWI T2 SWI T2 SWI T2 SWI T2 SWI T2 SWI T2
Mean Y Y Y N N N N Y Y Y N N N N Y Y Y Y N N
Skewness N N Y Y N N Y Y N N N Y N N Y Y N Y N Y
10 percentile Y Y Y N N N N N Y Y N Y N Y Y Y Y Y N N
th
90 percentile Y Y Y Y N N N Y Y Y N N N N Y Y Y Y N N
th
Total 3 3 4 2 0 0 1 3 3 3 0 2 0 1 4 4 3 4 0 1
Notes: Y: Yes; N: No; CE-SWI: Contrast-enhanced susceptibility-weighted imaging; RECIST: Response evaluation criteria in solid tumors.

overall performance advantage of CE-SWI volumetric Data curation: Elvis Duran Sierra, Mathew A.
and mChoi assessments over conventional T2-weighted Canjirathinkal, Behrang Amini
equivalents and traditional RECIST. The observed results Formal analysis: Raul Valenzuela, Elvis Duran Sierra,
align with the statistical power expected from a small sample Mathew A. Canjirathinkal, Behrang Amini
size, outlining the need for a larger population analysis to Funding acquisition: John E. Madewell, William A. Murphy Jr.
extend this pilot study. Methodology: Raul Valenzuela, Elvis Duran Sierra,
Mathew A. Canjirathinkal, Colleen M. Costelloe,
5. Conclusion John E. Madewell, William A. Murphy Jr.

RRR is relatively insensitive to volumetric tumor changes Writing – original draft: Raul Valenzuela, Elvis Duran
before RECIST progression and tends to be better tuned Sierra, Colleen M. Costelloe, John E. Madewell,
with T2* signal and enhancement changes. Our study William A. Murphy Jr.
suggests that the novel use of CE-SWI-based volumetric Writing – review and editing: Raul Valenzuela, Elvis Duran
and mChoi measurements could improve the prediction Sierra, Colleen M. Costelloe, John E. Madewell,
of response/progression in desmoid tumors by providing a William A. Murphy Jr., Behrang Amini
better assessment by means of 3D tumor size measurements
and could enhance the discrimination between the mature Ethics approval and consent to participate
collagenized component and the enhancing immature An approved waiver of consent was obtained for this
components, respectively, predominant in mature retrospective study.
responsive and immature progressive disease. In line
with these encouraging early results, a larger population Consent for publication
study that includes multifocal disease as a disease of An IRB granted a waiver of informed consent for this study.
interest, enrols RECIST-based positive response cases, and
performs treatment efficacy analysis is warranted. Availability of data

Acknowledgments Data can be obtained from corresponding author following
formal request.
None.
References
Funding
1. Fletcher CD, Unni K, Mertens F, 2002, World Health
This work was partly supported by M.R. Evelyn Hudson Organization classification of tumours. In: Pathology and
Foundation Endowed Professorship and the John S. Dunn, Genetics of Tumours of Soft Tissue and Bone. Lyon, France:
Sr. Distinguished Chair in Diagnostic Imaging. IARC press.

Conflict of interest 2. Crombé A, Kind M, Ray-Coquard I, et al., 2020, Progressive
desmoid tumor: Radiomics compared with conventional
The authors declare that they have no competing interests. response criteria for predicting progression during systemic
therapy-a multicenter study by the French sarcoma group.
Author contributions AJR Am J Roentgenol, 215(6): 1539–1548.
Conceptualization: Raul Valenzuela, Behrang Amini https://doi.org/10.2214/AJR.19.22635

Volume 2 Issue 3 (2023) 7 https://doi.org/10.36922/td.1414